10 Best Undervalued Healthcare Stocks for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market landscape is marked by heightened volatility and sector rotation, with healthcare stocks demonstrating resilience amid macroeconomic uncertainty. Our selection methodology leverages ValueSense’s proprietary intrinsic value models, focusing on companies with strong free cash flow, robust margins, and attractive valuations relative to their sector peers[1][2]. Each stock featured below was screened for quality ratings, undervaluation versus intrinsic value, and sector diversification, ensuring a balanced and opportunity-rich watchlist.
Featured Stock Analysis
AbbVie Inc. (ABBV)
| Metric | Value |
|---|---|
| Market Cap | $386.4B |
| Quality Rating | 6.1 |
| Intrinsic Value | $286.5 |
| 1Y Return | 8.0% |
| Revenue | $58.3B |
| Free Cash Flow | $18.2B |
| Revenue Growth | 6.1% |
| FCF margin | 31.3% |
| Gross margin | 74.3% |
| ROIC | 12.6% |
| Total Debt to Equity | (51,073.2%) |
Investment Thesis
AbbVie stands out as a leading pharmaceutical company with a market cap of $386.4B and a ValueSense quality rating of 6.1. The stock’s intrinsic value is calculated at $286.5, suggesting significant upside from current levels. AbbVie’s strong free cash flow $18.2B and high gross margin 74.3% underscore its operational efficiency. The company’s 1-year return of 8.0% and revenue growth of 6.1% reflect steady performance in a competitive sector.
Key Catalysts
- Expansion of immunology and oncology portfolios
- Continued strength in Humira and Rinvoq franchises
- Strategic acquisitions enhancing pipeline diversity
- Robust free cash flow supporting shareholder returns
Risk Factors
- High total debt to equity 51,073.2% raises leverage concerns
- Patent expirations impacting key revenue streams
- Regulatory risks in drug pricing and approvals
UnitedHealth Group Incorporated (UNH)
| Metric | Value |
|---|---|
| Market Cap | $310.1B |
| Quality Rating | 6.2 |
| Intrinsic Value | $598.9 |
| 1Y Return | -39.3% |
| Revenue | $435.2B |
| Free Cash Flow | $17.4B |
| Revenue Growth | 11.8% |
| FCF margin | 4.0% |
| Gross margin | 19.7% |
| ROIC | 19.0% |
| Total Debt to Equity | 78.9% |
Investment Thesis
UnitedHealth Group, with a market cap of $310.1B and a quality rating of 6.2, is a dominant force in managed healthcare. Despite a challenging year (-39.3% 1Y return), the company’s intrinsic value of $598.9 signals undervaluation. UNH’s revenue growth 11.8% and ROIC 19.0% highlight its ability to scale profitably, while its $17.4B free cash flow supports ongoing innovation and expansion.
Key Catalysts
- Expansion of Optum health services
- Integration of technology in healthcare delivery
- Diversification into pharmacy benefit management
- Strong revenue growth outpacing industry averages
Risk Factors
- Regulatory changes in Medicare/Medicaid reimbursement
- Competitive pressures from emerging health tech firms
- Debt to equity ratio 78.9% warrants monitoring
Novartis AG (NVS)
| Metric | Value |
|---|---|
| Market Cap | $241.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $137.7 |
| 1Y Return | 14.2% |
| Revenue | $55.5B |
| Free Cash Flow | $11.3B |
| Revenue Growth | 12.5% |
| FCF margin | 20.4% |
| Gross margin | 37.2% |
| ROIC | 19.1% |
| Total Debt to Equity | 71.6% |
Investment Thesis
Novartis, a global pharmaceutical leader, boasts a $241.1B market cap and a quality rating of 6.1. Its intrinsic value of $137.7 exceeds current trading levels, and the company’s 1-year return of 14.2% reflects investor confidence. Novartis’s revenue growth 12.5% and ROIC 19.1% position it for continued success in innovative therapies.
Key Catalysts
- Strong pipeline in oncology and gene therapies
- Geographic expansion in emerging markets
- Strategic divestitures improving core focus
- Consistent free cash flow $11.3B supports R&D
Risk Factors
- Currency fluctuations impacting international revenue
- Regulatory hurdles for new drug approvals
- Debt to equity ratio 71.6% requires attention
Novo Nordisk A/S (NVO)
| Metric | Value |
|---|---|
| Market Cap | $219.9B |
| Quality Rating | 6.5 |
| Intrinsic Value | $77.4 |
| 1Y Return | -55.8% |
| Revenue | DKK 311.9B |
| Free Cash Flow | DKK 62.0B |
| Revenue Growth | 20.9% |
| FCF margin | 19.9% |
| Gross margin | 83.9% |
| ROIC | 29.7% |
| Total Debt to Equity | 59.1% |
Investment Thesis
Novo Nordisk, with a $219.9B market cap and the highest quality rating in this list 6.5, specializes in diabetes and obesity treatments. Despite a -55.8% 1Y return, its intrinsic value $77.4 and exceptional gross margin 83.9% highlight its profitability. Revenue growth of 20.9% and a ROIC of 29.7% indicate operational excellence.
Key Catalysts
- Leadership in GLP-1 and insulin therapies
- Expansion into obesity and rare disease markets
- Strong free cash flow (DKK 62.0B) supports innovation
- High gross margin and ROIC drive shareholder value
Risk Factors
- Currency risk (DKK reporting)
- Competitive landscape in diabetes care
- Debt to equity ratio 59.1% is notable
Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $215.2B |
| Quality Rating | 7.1 |
| Intrinsic Value | $107.2 |
| 1Y Return | -15.3% |
| Revenue | $63.6B |
| Free Cash Flow | $14.7B |
| Revenue Growth | 1.8% |
| FCF margin | 23.1% |
| Gross margin | 81.2% |
| ROIC | 25.7% |
| Total Debt to Equity | 72.2% |
Investment Thesis
Merck, with a $215.2B market cap and a top-tier quality rating of 7.1, is a pharmaceutical powerhouse. Its intrinsic value $107.2 and gross margin 81.2% reflect strong fundamentals. While the 1-year return is -15.3%, Merck’s free cash flow $14.7B and ROIC 25.7% support ongoing investment in breakthrough therapies.
Key Catalysts
- Keytruda and oncology portfolio expansion
- Vaccine development and global distribution
- Strategic partnerships in biotech innovation
- High profitability metrics
Risk Factors
- Patent cliffs for major drugs
- Regulatory and pricing pressures
- Debt to equity ratio 72.2% is elevated
Abbott Laboratories (ABT)
| Metric | Value |
|---|---|
| Market Cap | $215.2B |
| Quality Rating | 6.8 |
| Intrinsic Value | $150.6 |
| 1Y Return | 9.6% |
| Revenue | $43.8B |
| Free Cash Flow | $4,626.0M |
| Revenue Growth | 6.4% |
| FCF margin | 10.6% |
| Gross margin | 55.0% |
| ROIC | 25.0% |
| Total Debt to Equity | N/A |
Investment Thesis
Abbott Laboratories, valued at $215.2B with a quality rating of 6.8, is a diversified healthcare company. Its intrinsic value $150.6 and 1-year return 9.6% point to solid performance. Abbott’s revenue growth 6.4% and ROIC 25.0% highlight its ability to innovate across diagnostics, medical devices, and nutrition.
Key Catalysts
- Growth in diagnostics and medical device segments
- Expansion into emerging markets
- Consistent free cash flow $4.6B supports R&D
- High gross margin 55.0% ensures profitability
Risk Factors
- Exposure to global supply chain disruptions
- Competitive pressures in diagnostics
- Debt metrics not available (N/A)
Thermo Fisher Scientific Inc. (TMO)
| Metric | Value |
|---|---|
| Market Cap | $214.5B |
| Quality Rating | 5.9 |
| Intrinsic Value | $583.6 |
| 1Y Return | 3.9% |
| Revenue | $43.7B |
| Free Cash Flow | $6,111.0M |
| Revenue Growth | 3.2% |
| FCF margin | 14.0% |
| Gross margin | 40.8% |
| ROIC | 8.3% |
| Total Debt to Equity | 69.9% |
Investment Thesis
Thermo Fisher Scientific, with a $214.5B market cap and a quality rating of 5.9, is a leader in scientific instrumentation and diagnostics. Its intrinsic value $583.6 and steady revenue growth 3.2% reflect a stable business model. The company’s free cash flow $6.1B and gross margin 40.8% support ongoing innovation.
Key Catalysts
- Expansion in life sciences and diagnostics
- Strategic acquisitions fueling growth
- Strong presence in research and clinical markets
- Consistent profitability
Risk Factors
- Slower revenue growth compared to peers
- High competition in scientific instrumentation
- Debt to equity ratio 69.9% is significant
Amgen Inc. (AMGN)
| Metric | Value |
|---|---|
| Market Cap | $160.6B |
| Quality Rating | 6.5 |
| Intrinsic Value | $434.9 |
| 1Y Return | -5.3% |
| Revenue | $34.9B |
| Free Cash Flow | $10.6B |
| Revenue Growth | 12.8% |
| FCF margin | 30.4% |
| Gross margin | 64.5% |
| ROIC | 11.7% |
| Total Debt to Equity | 756.7% |
Investment Thesis
Amgen, with a $160.6B market cap and a quality rating of 6.5, is a biotechnology leader. Its intrinsic value $434.9 and free cash flow $10.6B highlight financial strength. Despite a -5.3% 1Y return, Amgen’s revenue growth 12.8% and FCF margin 30.4% indicate robust operational performance.
Key Catalysts
- Expansion of biosimilars and innovative therapies
- Strong pipeline in oncology and inflammation
- High FCF margin supports shareholder returns
- Strategic acquisitions
Risk Factors
- High total debt to equity 756.7%
- Patent expirations for key products
- Regulatory risks
Pfizer Inc. (PFE)
| Metric | Value |
|---|---|
| Market Cap | $140.1B |
| Quality Rating | 6.3 |
| Intrinsic Value | $39.3 |
| 1Y Return | -10.1% |
| Revenue | $63.8B |
| Free Cash Flow | $12.4B |
| Revenue Growth | 14.7% |
| FCF margin | 19.5% |
| Gross margin | 66.2% |
| ROIC | 10.6% |
| Total Debt to Equity | 69.4% |
Investment Thesis
Pfizer, with a $140.1B market cap and a quality rating of 6.3, remains a major player in global pharmaceuticals. Its intrinsic value $39.3 and free cash flow $12.4B support ongoing innovation. The company’s 1-year return -10.1% and revenue growth 14.7% reflect a transition period post-pandemic.
Key Catalysts
- Expansion in vaccines and oncology
- Strategic partnerships and acquisitions
- Strong free cash flow supports R&D
- High gross margin 66.2%
Risk Factors
- Post-pandemic revenue normalization
- Competitive pressures in generics
- Debt to equity ratio 69.4%
Sanofi (SNY)
| Metric | Value |
|---|---|
| Market Cap | $123.2B |
| Quality Rating | 4.9 |
| Intrinsic Value | $94.6 |
| 1Y Return | -4.3% |
| Revenue | €42.1B |
| Free Cash Flow | €2,093.0M |
| Revenue Growth | (29.2%) |
| FCF margin | 5.0% |
| Gross margin | 72.6% |
| ROIC | 8.1% |
| Total Debt to Equity | 29.6% |
Investment Thesis
Sanofi, with a $123.2B market cap and a quality rating of 4.9, is a diversified pharmaceutical company. Its intrinsic value $94.6 and gross margin 72.6% indicate solid fundamentals, though the 1-year return -4.3% and revenue growth -29.2% suggest recent challenges.
Key Catalysts
- Expansion in specialty care and vaccines
- Strategic partnerships in rare diseases
- High gross margin supports profitability
- Focused R&D investments
Risk Factors
- Negative revenue growth
- Competitive pressures in core markets
- Debt to equity ratio 29.6% is moderate
Portfolio Diversification Insights
This watchlist offers broad sector diversification within healthcare, spanning pharmaceuticals, biotechnology, diagnostics, and managed care. The inclusion of large-cap companies with varying growth profiles and geographic exposures helps mitigate sector-specific risks. High-quality ratings and robust free cash flow across the portfolio support stability, while exposure to innovation and emerging markets enhances upside potential.
Market Timing & Entry Strategies
Given recent market volatility, staggered entry strategies—such as dollar-cost averaging—can help manage risk. Monitoring earnings releases, regulatory updates, and sector rotation trends is crucial for timing entries. ValueSense’s intrinsic value tools and sentiment analysis features enable investors to identify periods of undervaluation and capitalize on short-term dislocations[1][2].
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screener, focusing on intrinsic value, quality ratings, free cash flow, and sector diversification. Only companies meeting strict fundamental criteria and showing signs of undervaluation were included[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; Merck (MRK) and Novo Nordisk (NVO) stand out for their high quality ratings and strong ROIC, while AbbVie (ABBV) and Novartis (NVS) present compelling value based on intrinsic value calculations. The “best” depends on individual investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification is key to managing risk. This watchlist is designed to provide exposure across healthcare subsectors, balancing growth, stability, and innovation. Investors can select stocks that align with their portfolio strategy and risk profile.
Q4: What are the biggest risks with these picks?
Major risks include regulatory changes, patent expirations, competitive pressures, and high leverage in some companies. Monitoring debt levels, revenue growth trends, and sector-specific challenges is essential for risk management.
Q5: When is the best time to invest in these stocks?
Optimal entry points often coincide with periods of undervaluation, earnings releases, or sector rotation. ValueSense’s intrinsic value and sentiment analysis tools can help identify attractive buying opportunities based on real-time data and market trends[1][2].